Recent Updates
Recently added Catalysts
GKOS Positive Sentiment

Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28

Wednesday, October 7, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Glaukos Corporation is set to announce its third quarter 2026 financial results on October 28, 2026, after market close. The company specializes in treatments for glaucoma and other eye conditions. A conference call will follow the announcement, allowing management to discuss the results with investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Glaukos is focused on innovative therapies for eye diseases.
  • The upcoming financial results may show positive growth.
  • Management will engage with investors through a conference call.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+66%
120-day peak, hindsight
Typical move
8.7%
average across 4 past catalysts
Lead asset
Test Article A
Phase 3 · Progressive Keratoconus

Full Press Release Details

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release third quarter 2026 financial results after the market close on Wednesday, October 28, 2026. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on October 28, 2026. A link

Frequently Asked Questions

When will Glaukos release its Q3 2026 results?

Glaukos will release its Q3 2026 financial results on October 28, 2026.

What time is the Glaukos conference call?

The conference call will take place at 1:30 p.m. PT on October 28, 2026.

What is Glaukos focused on?

Glaukos specializes in therapies for glaucoma and other eye conditions.

How can I access the conference call?

The conference call will be available via a webcast link provided by Glaukos.

ShareAdd on Google
Tags: GKOS Glaukos financial results ophthalmic therapies glaucoma treatment
Last updated: Oct 7, 2026

Biotech snapshot

Cash runway
$286M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Test Article APhase 3
Progressive Keratoconus →

Catalyst track record

+66%
best trade around GKOS's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for GKOS.

See every catalyst's timing & PoA →